Allergy Therapeutics (AGY) — Net Asset Quality Index
Allergy Therapeutics (AGY) has a Net Asset Quality Index of -41.7% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX67.54 Million minus total liabilities of GBX95.74 Million yields net assets of GBX-28.19 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Allergy Therapeutics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Allergy Therapeutics Net Asset Quality Index Over Time (2002–2025)
This chart shows how Allergy Therapeutics's Net Asset Quality Index has evolved across 24 annual periods from 2002 to 2025. As of June 2025, the index stands at -41.7%, representing net assets of GBX-28.19 Million against total assets of GBX67.54 Million GBX. See Allergy Therapeutics current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Allergy Therapeutics (2002–2025)
The table below presents the year-by-year Net Asset Quality Index for Allergy Therapeutics from 2002 to 2025, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Allergy Therapeutics (AGY) total market value.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -41.7% | GBX-28.19 Million | GBX67.54 Million | GBX95.74 Million | ▼ -47.5 pp |
| 2024 | 5.7% | GBX3.71 Million | GBX64.83 Million | GBX61.12 Million | ▲ +2.6 pp |
| 2023 | 3.1% | GBX2.07 Million | GBX66.77 Million | GBX64.70 Million | ▼ -48.7 pp |
| 2022 | 51.8% | GBX37.77 Million | GBX72.95 Million | GBX35.18 Million | ▼ -3.3 pp |
| 2021 | 55.1% | GBX48.53 Million | GBX88.09 Million | GBX39.55 Million | ▲ +4.3 pp |
| 2020 | 50.8% | GBX43.78 Million | GBX86.22 Million | GBX42.44 Million | ▼ -4.1 pp |
| 2019 | 54.8% | GBX37.56 Million | GBX68.50 Million | GBX30.94 Million | ▲ +9.7 pp |
| 2018 | 45.2% | GBX23.03 Million | GBX51.02 Million | GBX27.98 Million | ▼ -7.3 pp |
| 2017 | 52.4% | GBX29.96 Million | GBX57.18 Million | GBX27.22 Million | ▼ -1.1 pp |
| 2016 | 53.5% | GBX30.32 Million | GBX56.68 Million | GBX26.36 Million | ▼ -14.5 pp |
| 2015 | 68.0% | GBX34.47 Million | GBX50.70 Million | GBX16.23 Million | ▲ +14.9 pp |
| 2014 | 53.1% | GBX15.07 Million | GBX28.40 Million | GBX13.32 Million | ▲ +2.4 pp |
| 2013 | 50.7% | GBX14.67 Million | GBX28.96 Million | GBX14.29 Million | ▼ -1.9 pp |
| 2012 | 52.6% | GBX14.59 Million | GBX27.75 Million | GBX13.16 Million | ▲ +45.6 pp |
| 2011 | 7.0% | GBX2.14 Million | GBX30.62 Million | GBX28.48 Million | ▼ -6.4 pp |
| 2010 | 13.3% | GBX3.89 Million | GBX29.11 Million | GBX25.23 Million | ▲ +118.3 pp |
| 2009 | -105.0% | GBX-23.18 Million | GBX22.08 Million | GBX45.25 Million | ▼ -56.3 pp |
| 2008 | -48.7% | GBX-11.29 Million | GBX23.18 Million | GBX34.47 Million | ▼ -84.5 pp |
| 2007 | 35.8% | GBX8.60 Million | GBX23.99 Million | GBX15.40 Million | ▼ -50.5 pp |
| 2006 | 86.3% | GBX32.70 Million | GBX37.88 Million | GBX5.18 Million | ▲ +11.0 pp |
| 2005 | 75.3% | GBX20.08 Million | GBX26.66 Million | GBX6.58 Million | ▲ +12.3 pp |
| 2004 | 63.0% | GBX7.08 Million | GBX11.23 Million | GBX4.16 Million | ▲ +13.2 pp |
| 2003 | 49.8% | GBX5.55 Million | GBX11.15 Million | GBX5.60 Million | ▲ +95.2 pp |
| 2002 | -45.5% | GBX-4.40 Million | GBX9.68 Million | GBX14.07 Million | — |